Aptose Biosciences Inc.

Precision Oncology for Therapies of Tomorrow

Aptose Biosciences is a science-driven clinical-stage biotechnology company developing first-in-class targeted agents to address the unmet clinical need in acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), chronic lymphocytic leukemia (CLL), non-Hodgkin’s lymphoma (NHL), and other hematologic malignancies.

Who We Are View Our Clinical Trials

Broad Applicability Across the Hematology Spectrum

Our drug candidates have been designed to provide safe single agent efficacy in multiple adjacent indications, as well as enhance the efficacy of other anti-cancer therapies and regimens without overlapping toxicities.

View Product Pipeline

HM43239: Myeloid Kinome Inhibitor (MKI) for AML

HM43239 is a potent oral inhibitor of key kinases operative in myeloid malignancies, including SYK, FLT3, JAK, c-KIT(mut), and others.

View Candidate

Luxeptinib: Lymphoid Kinome Inhibitor (LKI) for B-NHL

CG-806 is a potent non-covalent inhibitor of wildtype and mutant forms of BTK, as well as multiple oncogenic signaling pathways operative in CLL and other B-cell malignancies.

View Candidate

Luxeptinib: Myeloid Kinome Inhibitor (MKI) for AML/MDS

CG-806 potently inhibits wildtype and all mutant forms of FLT3 which are an oncogenic drivers in AML and MDS, as well as other oncogenic rescue pathways operative in myeloid malignancies.

View Candidate

Our Clinical Trials in Hematologic Malignancies

Currently, we have three ongoing clinical trials with our investigational drug candidates:

HM43239: Phase 1/2

HM43239 is in a Phase 1/2 clinical trial for the treatment of patients with relapsed or refractory AML

Luxeptinib: Phase 1a/b

Luxeptinib is in a Phase 1a/b clinical trial for the treatment of patients with B-cell malignancies, including CLL and NHL, who have failed or are intolerant to the standard treatments available.